SYRS vs. CUE, PGNX, ARCT, ALEC, CRBP, REPL, ALMS, SAVA, VECT, and YMAB
Should you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include Cue Biopharma (CUE), Progenics Pharmaceuticals (PGNX), Arcturus Therapeutics (ARCT), Alector (ALEC), Corbus Pharmaceuticals (CRBP), Replimune Group (REPL), Alumis (ALMS), Cassava Sciences (SAVA), VectivBio (VECT), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "medical" sector.
Cue Biopharma (NASDAQ:CUE) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation, dividends and community ranking.
Syros Pharmaceuticals received 217 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 63.96% of users gave Syros Pharmaceuticals an outperform vote while only 52.16% of users gave Cue Biopharma an outperform vote.
Cue Biopharma presently has a consensus target price of $5.80, indicating a potential upside of 765.67%. Syros Pharmaceuticals has a consensus target price of $14.00, indicating a potential upside of 125.08%. Given Syros Pharmaceuticals' higher possible upside, equities research analysts plainly believe Cue Biopharma is more favorable than Syros Pharmaceuticals.
Cue Biopharma has higher earnings, but lower revenue than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Cue Biopharma has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500.
In the previous week, Cue Biopharma had 7 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 9 mentions for Cue Biopharma and 2 mentions for Syros Pharmaceuticals. Cue Biopharma's average media sentiment score of 0.94 beat Syros Pharmaceuticals' score of 0.44 indicating that Syros Pharmaceuticals is being referred to more favorably in the news media.
Cue Biopharma has a net margin of -711.84% compared to Cue Biopharma's net margin of -1,656.34%. Syros Pharmaceuticals' return on equity of -128.30% beat Cue Biopharma's return on equity.
35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 7.5% of Cue Biopharma shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Cue Biopharma beats Syros Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Syros Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syros Pharmaceuticals Competitors List
Related Companies and Tools
Free SYRS Stock Alerts